Document 0976
 DOCN  M9570976
 TI    Innovative treatments for Kaposi's sarcoma (Meeting abstract).
 DT    9506
 AU    Conant MA; University of California Medical Center, San Francisco, CA
 SO    Melanoma Res; 3:8 1993. Unique Identifier : AIDSLINE ICDB/95607236
 AB    New approaches in the management of Kaposi's sarcoma (KS) have been
       developed in the past three years, including new delivery mechanisms,
       autologous CD-8 expansion and cytokine development. At the Berlin AIDS
       Conference it was shown that 5-FU in an implant containing collagen and
       epinephrine was safe. The response to the placebo was as good as the
       response to the agent, which raises the question of the mechanism of
       action of the placebo. Systemic daunorubicin incorporated in liposomes
       has been tested for the past two years. In Berlin, Chew and Goebel
       reported that this combination is well tolerated and preliminary data
       suggest it may have great promise in targeting the lesions of KS in high
       doses while sparing the patient from some toxic side effects. At last
       year's AIDS Conference, autologous CD-8 cell expansion was reported to
       show dramatic benefit in one patient with KS. In Berlin, Klimas reported
       that five out of six patients showed partial responses as defined by 25%
       lesion reduction with ex vivo CD-8 expansion reinfusion and infusion of
       IL-2. Unfortunately, when patients were receiving expanded CD-8 cells,
       new lesions of KS were observed. Last year, oncostatin-M appeared to be
       involved in the proliferation of KS in vitro; stimulating interest in
       identifying cytokines and growth factors possibly responsible for its
       development. Huang et al recently demonstrated that growth factor FGF-5
       could be identified in four out of six patients with KS, but not in the
       adjacent normal skin of the same patient. This finding suggests that
       this growth factor may play a role in the pathogenesis of KS. The
       identification of the growth factor or cytokine responsible for KS will
       create the possibility of blocking this agent, using appropriate
       recombinant technology.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Cytokines/PHYSIOLOGY
       Fibroblast Growth Factor/PHYSIOLOGY  Human  Sarcoma,
       Kaposi's/ETIOLOGY/METABOLISM/PATHOLOGY/*THERAPY  *T-Lymphocytes,
       Suppressor-Effector  Tumor Cells, Cultured  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).